Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Lu Zhao1,2†, Qingyun Mei1,2†, Yongchao Yu1,2, Na Wang1,2, Dou Zhang1,2, Dongying Liao1,2, Jinhui Zuo1,2, Hongxia Xie1,2, Yingjie Jia1,2 and Fanming Kong1,2*

1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, 2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China

Great progress has been made in the treatment of driver gene-positive Non-Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.

Keywords: NSCLC, RET fusion, targeted therapy, drug resistance, immunotherapy

INTRODUCTION

Lung cancer ranks second among malignant tumors in the world, the long-term outcome is still poor (1). Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% (2). Most NSCLC patients were diagnosed at an advanced stage, and platinum-containing combination chemotherapy was the main treatment, but the five-year survival rate was only approximately 15% (3). The incidence of RET fusion in NSCLC was 0.7% - 2% and was associated with younger age and never-smoker status (4). Among the 12 identified fusion genes, the most common partner genes were KIF5B, CCDC6, and NCOA4 (5).

RET, acting as a proto-oncogene, was first identified in NIH/3T3 cells from transformed mice in 1985 (6). It was located on chromosome 10q11.2 and contained 21 exons with a full length of 60 kb (7). It encodes the RET transmembrane receptor kinase, which is needed for proliferation, differentiation, migration (8–10). RET fusion could activate the downstream PI3K/AKT, RAS/MAPK, and JAK/STAT pathways, which further promoted tumor proliferation, differentiation, migration. The clinicopathological characteristics of RET fusion NSCLC were as follows: younger age (60 years old), never smoking, adenocarcinoma, smaller volume (≤3 cm), lymph node metastasis, low differentiation (11, 12). It was less likely to have other oncogenic driver genes together, suggesting its own oncogenic driver potential. Moreover, RET fusion was also associated with a high risk of metastasis to the brain (13).

Currently, RET-selective TKIs such as pralsetinib and selpercatinib were the main treatments for RET fusion NSCLC patients. The acquired drug resistance was found in the clinical. And the platinum-containing chemotherapy or Immune-Checkpoint Inhibitors (ICIs) was explored as therapeutic choice after drug resistance. This article systematically reviewed the recent advances in the treatments for RET fusion NSCLC, provided current challenges and described proposals for improving the future clinical management of the disease.
RET-SELECTIVE TKIS

Selpercatinib (Retevmo)

Selpercatinib was a highly selective RET inhibitor that could block the adenosine triphosphate binding site of RET receptor tyrosine kinase (14). Because of good properties in target specificity, tolerability, and intracranial efficacy, Selpercatinib became a new valid option for many European patients (15). A total of 105 RET fusion NSCLC patients enrolled in the phase 1/2 LIBRETTO-001 trial received the Selpercatinib treatment had promising ORR (64%) and mDoR (17 months), and the mPFS of these patients was 16 months (16–18) (Table 1). Based on the anti-tumor efficacy and safety, Selpercatinib was approved by FDA for RET fusion NSCLC on May 8, 2020. In 2021, Selpercatinib was approved by the EMA and Swiss-Medic for second line or posterior line therapy. The clinical trial LIBRETTO-321 was conducted to evaluate the efficacy of Selpercatinib for Chinese RET fusion NSCLC patients. The ORR was 61.1% in the Selpercatinib treated population. 90% of the patients remained in continuous remission after 6 months (19). This study indicated that Selpercatinib was also a promising therapeutic option for Chinese RET fusion NSCLC patients. Currently, two large clinical studies, namely, LIBRETTO-121 and LIBRETTO-431 are ongoing to explore the efficacy of Selpercatinib in advanced solid tumors (20, 21).

Pralsetinib (Gavreto)

Pralsetinib was the second selective RET inhibitor with highly potent and selective for wild-type RET, RET fusion (including the most common KIF5B-RET and CCDC6-RET), and mutations (RET V804 L, RET V804 M, and RET M918T) (22). The clinical activity and safety of Pralsetinib was investigated by the ARROW study (Global multicentric single-arm phase I/II trial) (23). Based on the result of this study, Pralsetinib was approved as first-line or post-line treatment for RET fusion NSCLC by FDA in September 2020 (24, 25). Updated data reported by the American Society of Clinical Oncology (ASCO) in 2021 showed that the ORR was 17.1 months, the CR was 6%, and the mPFS was 16.5 months (n=136). Nine patients with measurable brain metastases all showed an intracranial reduction to a certain extent (intracranial response rate 56%, intracranial CR 33%) (Table 1). As the excellent efficacy and low off-target toxicity in RET cancer patients, Pralsetinib was also approved by China’s State Food and Drug Administration (NMPA) in March, 2021 (26). This is the first RET inhibitor approved in China and is of great significance (27–29).

NONSELECTIVE MULTITARGETED TKIS

Cabozantinib

Cabozantinib was a multikinase inhibitor against RET, VEGFR2, MET, ROS1, AXL, c-KIT, TIE2, and FLT3 (30). The clinical application of Cabozantinib was limited due to multi-target inhibition and the off-target effects (Table 1). A 2016 phase II clinical study consisting of 26 patients with RET fusion showed a mPFS of 5.5 months, a mOS of 9.9 months, and overall efficiency of only 28% (31). The overall efficiency of Cabozantinib for RET fusion patients was significantly lower than ALK/ROS1 gene fusion and EGFR mutation patients (32). Other results from the global multicenter registry also showed unsatisfactory clinical effect and highly incidence of grade 3/4 adverse effects (33–36).

Vandetanib

Vandetanib was a multikinase inhibitor that inhibits VEGFR, EGFR, and RET (37). In the LURET phase II study, the enrolled 19 Japanese RET fusion patients received the Vandetanib treatment, the median PFS was 4.7 months, the median OS was 11.1 months, and the overall survival rate at 12 months was 52.6%. Eleven patients (57.9%) had adverse events leading to a dose reduction (38). Another phase II study explored the efficacy of Vandetanib in Korean patients with metastatic or recurrent RET fusion NSCLC. The study showed that the median PFS was

TABLE 1 | MKI and TKI in RET fusion NSCLC.

| NCT-number | Trial group | Trial Design | primary end points | Secondary end point | Adverse reactions greater than or equal to grade 3 |
|------------|-------------|-------------|--------------------|--------------------|---------------------------------------------|
| Pralsetinib (BLU-667) (NCT03037385) | 233 patients with RET fusion-positive NSCLC | The phase 1 dose escalation part of the trial determined the maximum tolerated dose The phase 2 dose expansion part evaluated the safety and activity of pralsetinib in multiple expansion groups | mPFS: 9.1 months ORR: 53% mDOR: 17 months Gr3-4 treatment-related Pralsetinib=48% | RR: 33% mPFS: 16 months | |
| Selpercatinib (LOXO-292) (NCT03157128) | 253 patients with RET fusion-positive NSCLC | Selpercatinib, 160 mg orally twice daily, was administered in consecutive 28-day cycles until disease progression | mPFS: 5.5 months ORR: 28% mDOR: 17 months Gr3-4 treatment-related Selpercatinib=NR | mOS: 9.9 months | Gr3-4 treatment-related Selpercatinib=NR |
| Cabozantinib (NCT01639508) | 26 patients with RET fusion-positive NSCLC | Patients were given 60 mg of cabozantinib orally per day until disease progression | mPFS: 6.5 months ORR: 64% mDOR: 17 months Gr3-4 treatment-related Cabozantinib=46% | RR: 28% mOS: 13.5 months | Gr3-4 treatment-related Cabozantinib=46% |
| Vandetanib (UMIN0000010095) | 19 patients with RET fusion-positive NSCLC | Patients were continuously received 300 mg of oral vandetanib daily until disease progression | mPFS: 9.9 months ORR: 50% mDOR: 19.5 months Gr3-4 treatment-related Vandetanib=84.2% | RR: 47% mOS: 13.5 months | Gr3-4 treatment-related Vandetanib=84.2% |
4.5 months, the median OS was 11.6 months (Table 1). The most common grade 3 AEs were hypertension (17%), a prolonged QTc interval (11%), and transaminitis (6%) (39).

**Other MKIs**

Other MKIs had limited clinical data, and since the development of selective TKIs, they may have less attention. In 2017, a global multicenter RET registry study (GLORY) retrospectively explored the efficacy of RET fusion NSCLC patients using varieties of MKIs. At the time of the analysis, only 15% of the patients were continuing their treatment. This indicated that most patients did not benefit from these MKIs. As Table 2 showed, Lenvatinib only had an ORR of 16% in phase 2 multicenter trial (46, 47). The optimal response of sorafenib was SD, with no objective response (48). Sunitinib has a similar TKI activity profile to sorafenib but showed slightly better activity with a DCR of 55% (49). Other experimental drugs with Anti-Ret activity but limited preclinical data include apatinib, AD80, and dovitinib (50). However, the clinical efficacy has not yet been demonstrated.

**CHEMOTHERAPY**

Until the appearance of specific RET inhibitors, chemotherapy was still the primary treatment for RET fusion NSCLC. Some studies showed that these patients were sensitive to pemetrexed-based regimens. In the GLORY global study, 108 advanced NSCLC patients with RET fusion received first-line chemotherapy, the median PFS was 6.6 and 7.8 months, while the median OS was 23.6, 24.8 months, respectively (45, 51). In summary, chemotherapy could bring some clinical benefits for RET fusion NSCLC. Before the clinical accessibility or inapplicable of targeted drugs, platinum-based regimens was still the primary treatment for RET fusion NSCLC. Some studies were summarized to assess the efficacy of ICIs treatment in RET fusion NSCLC patients.

**ICIS**

Immune checkpoint inhibitors (ICIs) have become the standard treatment for driver gene-negative metastatic NSCLC. However, it proved poorly effective in patients with positive driver gene mutations, such as EGFR and ALK positive patients. The efficacy of ICIs in RET fusion NSCLC was insufficiency. The existing studies were summarized to assess the efficacy of ICIs treatment in RET fusion NSCLC patients.

**ICIs as First-Line Treatment**

In a single-center retrospective study, 4 RET fusion NSCLC patients and 1 RET-mutant NSCLC patient received ICIs treatment, and the mPFS and mOS were 3.0 months and 14.9 months, respectively (40). In a single-center retrospective study of Korea, the efficacy of Vandetanib was compared to chemotherapy in 59 RET fusion NSCLC patients, the ORR was 15.8% in the Vandetanib group, while 63% in chemotherapy group. For the ICIs group, the ORR was 7.7%, the PFS was 2.1 months, and the OS was 12.4 months (43). In contrast, another retrospective analysis of 45 Chinese patients showed no significant difference in PFS obtained with MKI vs. chemotherapy vs. ICIs treatment (3.8 vs. 3.5 vs. 2.5 months), the 10 evaluable patients treated with ICIs had an ORR of 20% (44). The difference between Chinese and Korean patients indicated that ICIs treatment remained controversial in RET fusion NSCLC patients (Table 2).

ICIs combined with chemotherapy therapy could be a choice for RET fusion NSCLC patients. In a retrospective real-world study, 12 patients with RET fusion NSCLC were treated with palivizumab combined with chemotherapy, the ORR was 58%, mPFS was 5.4 months, and OS was 19 months (52). Subsequently, Hess, et al. have verified the clinical benefit of the above chemotherapy combined with ICIs in 9 RET fusion NSCLC patients. The ORR was 66% and mPFS 6.6 months (Table 2) (41, 53, 54).

**ICIs as Post-Line Treatment**

In a multicenter retrospective study, 11 RET fusion NSCLC patients received ICIs in the post-line treatment. The DCR was up to 60% (41, 55). This result suggested that some patients in second-line and post-line treatment could benefit from ICIs. The comprehensive guidelines recommend that ICIs as a second-line treatment for RET fusion NSCLC patients (Table 2).

**COMBINED THERAPY**

Vandetanib in combination with everolimus brought about remission in all six RET fusion-positive NSCLCs. It also showed antitumor activity in refractory cases with cabozantinib and brain metastasis. Besides MET amplification was detected in four patients in the LIBRETTO-001 study, combination treatment with the selpercatinib+MET/ALK/ROS1 inhibitor crizotinib also showed clinical activity and good tolerability (42). In summary, combined treatment methods may provide clinical benefit to patients with RET fusion NSCLC, but their safety needs to be further verified.

| Table 2 | ICIs in RET fusion NSCLC. |
|-----------------|-----------------|-----------|-----------|
| Reference       | Characteristics | ORR (%)   | mPFS (months) | mOS (months) |
| Dudnik E et al. (40) | RET fusion (n=4) | 0         | 3          | 14.9        |
| Guisier F et al. (41) | RET fusion (n=9) | 37.5      | 7.6        | Not available |
| Hegde A et al. (42) | RET fusion (n=16) | Not available | 3.4 | Not available |
| Lee J et al. (43) | RET fusion (n=13) | 7.7        | 2.1        | 12.4        |
| Lu C et al. (42) | RET fusion (n=10) | 20         | 2.5        | Not available |
| Mazières J et al. (44) | RET fusion (n=16) | 6           | 2.1        | 21.3        |
| Ofirn M et al. (45) | RET fusion (n=19) | Not available | 3.4 | Not available |

Frontiers in Oncology | www.frontiersin.org May 2022 | Volume 12 | Article 894214
**DRUG RESISTANCE**

**Mechanisms of On-Target Drug Resistance**

It was an intratarget kinase-acquired resistance that dynamically evolves under kinase inhibitor selection pressure, making the kinase continuously activated under medication conditions. Gatekeeper mutations and solvent-front mutations were included. It has been reported that resistance mechanisms in MKIs include RET V804 M gatekeeper mutations and RET S904F (55). The selective RET inhibitor Selpercatinib and Pralsetinib induced a pre-lytic mutation (G810A/S) (56). It also demonstrated that it increased kinase activity and conferred resistance through allosteric effects. AXL overexpression and RAS mutations were subsequently reported in two RET fusion-positive cell lines resistant to multikinase inhibitors (22). Selective RET inhibitors have been designed to overcome gatekeeper mutations. The concurrent RET V804M gatekeeper mutation was associated with a G810 resolute mutation in an NSCLC patient.

**Mechanisms of Off-Target Drug Resistance**

The mechanisms of off-target resistance included the reactivation of different intracellular pathways, bypassing targeted receptor kinase-mediated signals. MET dependence has been reported as a recurrent and potential targeting mechanism for resistance to Selpercatinib and Pralsetinib (19, 57). A study that analyzed 20 RET fusion NSCLC patients who were resistant to Selpercatinib and Pralsetinib, the study found there were 3 (15%) MET amplification, 2 (10%) solvent G810C/S resistance, and 1 (5%) KRAS amplification. Recently, BRAF V600E mutation following Selpercatinib treatment was reported in KIF5B-RET fusion NSCLC patient.

**Next-Generation of RET-TKIs**

Currently, the next generation of RET-TKIs is under exploration. TPX-0046 is an efficient, selective, new generation of RET/SRC inhibitors. TPX-0046 is different in both structure and mechanism from Pralsetinib (Gavreto) and Selpercatinib (Retevmo). At present, TPX-0046 has been confirmed to have a clinical effect in patients (13, 58). BOS172738 is a targeted inhibitor of aberrant mutations in RET. A phase I clinical trial of BOS172738 reported that BOS172738 showed good safety for long-term administration. The overall efficacy ORR assessed by the investigator was 33% (n=18/54), and the NSCLC cohort ORR was 33% (n=10/30) (18, 59). Currently, multiple clinical trials are being conducted, including LIBRETTO-431, LIBRETTO-531, NCT04211337, and NCT03780517 (60).

**SUMMARY AND PROSPECTS**

The RET fusion NSCLC patients were advanced at diagnosis and had a poor prognosis. The highly selective RET inhibitors Selpercatinib and Pralsetinib provided new options for the treatment of RET fusion NSCLC patients. The occurrence of acquired resistance deserves attention, the next generation of RET TKIs or the novel therapeutic model were urgently need to be explored.

**AUTHOR CONTRIBUTIONS**

LZ and QM contributed equally to this work. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work is supported by the National Natural Science Foundation of China (No. 81403220), Tianjin Health and family planning-high level talent selection and training project, National key research and development (R&D) plan (2018YFC1707400).
12. Lu C, Zhou Q. Diagnostics, Therapeutics and Ret Inhibitor Resistance for Ret Fusion-Positive Non-Small Cell Lung Cancers and Future Perspectives. Cancer Treat Rev (2021) 96:102153. doi: 10.1016/j.ctrv.2021.102153
13. Rebuazi SE, Zullo L, Rossi G, Grassi M, Murriani V, Tagliamento M, et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol Sci (2021) 22(5):2625. doi: 10.3390/ijms22052625
14. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy of Selpercatinib in Ret Fusion-Positive Non-Small-Cell Lung Cancer. New Engl J Med (2020) 383(9):813–24. doi: 10.1056/NEJMoa2005653
15. Pall G, Gautschi O. Advances in the Treatment of Ret-Fusion-Positive Lung Cancer. Lung Cancer (Amsterdam Netherlands) (2021) 156:136–9. doi: 10.1016/j.lungcan.2021.04.017
16. Illini O, Hochmair MJ, Fabianik H, Weingerinde C, Tufman A, Swalduz A, et al. Selpercatinib in Ret Fusion-Positive Non-Small-Cell Lung Cancer (Siren): A Retrospective Analysis of Patients Treated Through an Access Program. Ther Adv Med Oncol (2021) 13:17588359211091675, doi: 10.1177/17588359211091675
17. Subbiah V, Velchetti V, Tuch BB, Ebata K, BussaID NL, Cabanillas ME, et al. Selective Ret Kinase Inhibition for Patients With Ret-Altered Cancers. Ann oncol: Off J Eur Soc Med Oncol (2018) 29(8):1869–76. doi: 10.1093/annonc/mdy137
18. Lin JJ, Liu SV, McCoach CE, Zhu VW, Tan AC, Yoda S, et al. Mechanisms of Resistance to Selective Ret Tyrosine Kinase Inhibitors in Ret Fusion-Positive Non-Small-Cell Lung Cancer. Ann oncol: Off J Eur Soc Med Oncol (2020) 31(12):1725–33. doi: 10.1093/annonc/mdaa095.009.015
19. Subbiah V, Shen T, Tezryan SS, Liu X, Hu X, Patel KP, et al. Structural Basis of Acquired Resistance to Selpercatinib and Pralsetinib Mediated by Non-Gatekeeper Ret Mutations. Ann oncol: Off J Eur Soc Med Oncol (2021) 32(2):261–8. doi: 10.1093/annonc/mdaa105.0599
20. Della Corte CM, Morgillo F. Rethinking Treatment for Ret-Altered Lung and Thyroid Cancers: Selpercatinib Approval by the Ema. J Am Assoc Cancer Res (2020) 13(5):1091. doi: 10.3390/cancers13051091
21. Hida T, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, et al. A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer. Ann J Clin Cancer Res (2021) 44(9):456–62. doi: 10.1016/j.annrco.2019.09.015
22. Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, et al. Characteristics and Treatment Outcomes of Ret Gene Fusion Among Chinese Patients With Lung Cancer. Jpn J Clin Oncol (2021) 51(9):102153. doi: 10.1016/j.jjco.2021.09.011
23. Spanheimer PM, Bashir A, Lorenzen AW, Beck AC, Liao J, Lizarraga IM, et al. A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer. Ann J Clin Cancer Res (2021) 14(2):dmm047779. doi: 10.1242/dmm.047779
24. Wang Y, Xu Y, Wang X, Sun C, Guo Y, Shao G, et al. Ret Fusion in Advanced Non-Small-Cell Lung Cancer and Response to Cabozantinib: A Case Report. Medicine (2019) 98(51):e14120. doi: 10.1097/mdco.00000000000014120
25. Xing P, Yang N, Hu X, Mu Y, Wang S, Guo Y, et al. The Clinical Significance of Ret Gene Fusion Among Chinese Patients With Lung Cancer. Trans Cancer Res (2020) 9(10):6455–63. doi: 10.21037/tcr-20-754
26. Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, et al. Phase I Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. Clin Lung Cancer (2019) 20(3): e317–e28. doi: 10.1016/j.clc.2018.12.018
27. Roskoski Jr., Sadeghi-Nejad A. Role of Ret Protein-Tyrosine Kinase Inhibitors in the Treatment of Ret-Driven Thyroid and Lung Cancers. Pharmacol Res (2018) 128:1–17. doi: 10.1016/j.phrs.2017.12.021
28. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Nccn Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Cancer Network: JNCCN (2021) 19(3):254–66. doi: 10.6004/jnccn.2021.0013
29. Spanheimer PM, Bashir A, Lorenzen AW, Beck AC, Liao J, Lizarraga IM, et al. A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer. Ann J Clin Cancer Res (2021) 44(9):456–62. doi: 10.1016/j.annrco.2019.09.015
30. Yoh K, Kato T, Satouchi M, Nishio M, Yamamoto N, Murakami H, et al. Final Survival Results for the Luret Phase II Study of Vandetanib in Previously Treated Patients With Ret-Rearranged Advanced Non-Small Cell Lung Cancer. Lung Cancer (Amsterdam Netherlands) (2021) 155:40–5. doi: 10.1016/j.lungcan.2021.03.002
31. Wang M, Naganna N, Sintim HO. Identification of Nicotinamide Aminonaphthyridine Compounds as Potent Ret Kinase Inhibitors and Antitumor Activities Against Ret Rearranged Lung Adenocarcinoma. Bioorganic Chem (2019) 90:103052. doi: 10.1016/j.bioorg.2019.103052
32. Dubnik E, Bshara E, Grubstein A, Fridel L, Shochat T, Roisman LC, et al. Rare Targetable Drivers (Rdks) in Non-Small Cell Lung Cancer (Nsclc): Outcomes With Immune Check-Point Inhibitors (Ipi). Lung Cancer (Amsterdam Netherlands) (2018) 124:117–24. doi: 10.1016/j.lungcan.2018.07.044
33. Dantoing E, Piton N, Salain M, Thiberville L, Guissier F. Anti-Pd1/Pd-L1 Immunotherapy for Non-Small-Cell Lung Cancer: Actionable Oncogenic Driver Mutations. Int J Mol Sci (2021) 22(12):6288. doi: 10.3390/jms22126288
34. Spanheimer PM, Bashir A, Lorenzen AW, Beck AC, Liao J, Lizarraga IM, et al. Overcoming Met-Dependent Resistance to Selective Ret Inhibition in Patients With Ret-Fusion-Positive Lung Cancer by Combining Selpercatinib With Cabozantinib. Clin Cancer Res an Off J Am Assoc Cancer Res (2021) 27(1):42–42. doi: 10.1158/1078-0432.Ccr-20-2278
35. Lee J, Ku RM, Shim JH, La Choi Y, Sun JM, Lee SH, et al. Characteristics and Outcomes of Ret-Rearranged Korean Non-Small Cell Lung Cancer Patients in Real-World Practice. Ipn J Clin Oncol (2020) 50(5):594–601. doi: 10.1093/jjco/hyaa019
36. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune Checkpoint Inhibitors for Patients With Advanced Lung Cancer and Oncogenic Driver Alterations: Results From the ImmunoTarget Registry. Ann oncol: Off J Eur Soc Med Oncol (2021) 30(8):1321–8. doi: 10.1093/annonc/mda167
37. Hida T, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, et al. Phase 2 Study of Lenvatinib in Patients With Ret-Fusion-Positive Lung Adenocarcinoma. Lung Cancer (Amsterdam Netherlands) (2019) 138:124–30. doi: 10.1016/j.lungcan.2019.09.011
38. Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, et al. Phase II Study of Alecintinib in Lung Cancer With Ret Fusion Gene: Study Protocol. J Med invest: JMI (2017) 64(3-4):317–20. doi: 10.2152/jmi.64.317
39. Horiike A, Takeuchi K, Uenami T, Kawano Y, Tanimoto A, Kaburaki K, et al. Sorafenib Treatment for Patients With Ret-Fusion-Positive Non-Small Cell LungenCancers (2020) 156:136–9. doi: 10.1016/j.lungcan.2021.04.017
Lung Cancer. Lung Cancer (Amsterdam Netherlands) (2016) 93:43–6. doi: 10.1016/j.lungcan.2015.12.011

49. Ferrara R, Auger N, Audin E, Bese B. Clinical and Translational Implications of Ret Rearrangements in Non-Small Cell Lung Cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer (2018) 13(1):27–45. doi: 10.1016/j.jtho.2017.10.021

50. Lin C, Wang S, Xie W, Zheng R, Gan Y, Chang J. Apatinib Inhibits Cellular Invasion and Migration by Fusion Kinase Kif5b-Ret Via Suppressing Ret/Src Signaling Pathway. Oncotarget (2016) 7(37):59236–44. doi: 10.18632/oncotarget.10985

51. Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, et al. Clinical Outcomes With Pemetrexed-Based Systemic Therapies in Ret-Rearranged Lung Cancers. Ann Oncol Off J Eur Soc Med Oncol (2016) 27(7):1286–91. doi: 10.1093/annonc/mdw163

52. Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, et al. Immune Checkpoint Inhibitor Treatment in Patients With Oncogene-Addicted Non-Small Cell Lung Cancer (Nsclc): Summary of a Multidisciplinary Round-Table Discussion. ESMO Open (2019) 4(3): e000498. doi: 10.1136/esmoopen-2019-000498

53. Hess LM, Han Y, Zhu YE, Bhandari NR, Sireci A. Characteristics and Outcomes of Patients With Ret-Fusion Positive Non-Small Lung Cancer in Real-World Practice in the United States. BMC Cancer (2021) 21(1):28. doi: 10.1186/s12885-020-07714-3

54. Codony-Servat J, Garcia-Roman S, Molina-Vila M, Bertran-Alamillo J, Viteri S, d’Hondt E, et al. Anti-Epidermal Growth Factor Vaccine Antibodies Increase the Antitumor Activity of Kinase Inhibitors in Alk and Ret Rearranged Lung Cancer Cells. Trans Oncol (2021) 14(1):100887. doi: 10.1016/j.tranon.2020.100887

55. Solomon BJ, Tan L, Han JJ, Wang SQ, Hollizeck S, Ebata K, et al. Ret Solvent Front Mutations Mediate Acquired Resistance to Selective Ret Inhibition In Ret-Driven Malignancies. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer (2020) 15(4):541–9. doi: 10.1016/j.jtho.2020.01.006

56. Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, et al. Sequential Alk Inhibitors Can Select for Lorlatinib-Resistant Compound Alk Mutations in Alk-Positive Lung Cancer. Cancer Discov (2018) 8(6):714–29. doi: 10.1158/2159-8290.Cd-17-1256

57. Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, et al. Resistance to Ret-Inhibition in Ret-Rearranged Nsclc Is Mediated by Reactivation of Ras/Mapk Signaling. Mol Cancer Ther (2017) 16(8):1623–33. doi: 10.1158/1535-7163.Mct-17-0008

58. Tan L, Solomon BJ. Defining Resistance Mechanisms to Selective Ret Tyrosine Kinase Inhibitors in Ret Fusion-Positive Non-Small-Cell Lung Cancer. Ann Oncol Off J Eur Soc Med Oncol (2020) 31(12):1599–600. doi: 10.1016/j.annonc.2020.10.002

59. Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, et al. Landscape of Acquired Resistance to Osimertinib in Egfr-Mutant Nsclc and Clinical Validation of Combined Egfr and Ret Inhibition With Osimertinib and Blu-667 for Acquired Ret Fusion. Cancer Discov (2018) 8(12):1529–39. doi: 10.1158/2159-8290.Cd-18-1022

60. Suda K, Mitsudomi T. Emerging Oncogenic Fusions Other Than Alk, Ros1, Ret, and Ntrk in Nsclc and the Role of Fusions as Resistance Mechanisms to Targeted Therapy. Trans Lung Cancer Res (2020) 9(6):2618–28. doi: 10.21037/tlcr-20-186

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhao, Mei, Yu, Wang, Zhang, Liao, Zuo, Xie, Jia and Kong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.